Niwat Saksit

Niwat Saksit

Auto-generated profile, based on publicly available information

Niwat Saksit

Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
NPNapat Prabmeechai
Napat Prabmeechai
CSChonlaphat Sukasem
Chonlaphat Sukasem
TKThachanan Kongpan
Thachanan Kongpan
PKParinya Konyoung
Parinya Konyoung
PCPansu Chumworathayi
Pansu Chumworathayi
WTWongwiwat Tassaneeyakul
Wongwiwat Tassaneeyakul
Phenytoin is one of the most common causative drugs of several types of severe cutaneous adverse reactions (SCAR) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reactions with eosinophilia and systemic symptoms (DRESS). Genetic polymorphisms of the human leukocyte antigens (HLA) and cytochromes P450 (CYP) have been proposed as key elements for the susceptibility to phenytoin-related SCAR in certain ethnicities. This study investigated the associations between the genetic polymorphisms of HLA class I and CYP2C9 and phenytoin-related SCAR in a Thai population. Sixty phenytoin-related SCAR (i.e. 39 SJS/TEN and 21 DRESS) and 92 phenytoin-tolerant patients were enrolled in the study. The genotypes of HLA class I and CYP2C9 were determined. Six HLA alleles including HLA-A*33:03, HLA-B*38:02, HLA-B*51:01, HLA-B*56:02, HLA-B*58:01, and HLA-C*14:02 were significantly associated with phenytoin-related SJS/TEN, whereas only the HLA-B*51:01 was significantly associated with phenytoin-related DRESS. The odds ratios of phenytoin-related SJS/TEN in the patients who carried one of these alleles ranged from 4- to 10-fold. The frequencies of patients who carried the HLA-B*15:02 in the SJS/TEN (12.82%) or the DRESS (9.52%) groups were not significantly different from that of the controls (14.13%). The higher risk of phenytoin-related SJS/TEN was observed in the patients with CYP2C9*3 (odds ratio=4.30, 95% confidence interval=1.41-13.09, P<0.05). Neither SJS/TEN nor DRESS caused by phenytoin was significantly associated with the HLA-B*15:02. The CYP2C9*3 variant was significantly associated with phenytoin-related SJS/TEN, but not DRESS. Certain alleles of HLA, particularly HLA-B*56:02, were significantly associated with phenytoin-related SCAR in the study population.

1 December 2017 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
TTTherdpong Tempark
Therdpong Tempark
PSPatompong Satapornpong
Patompong Satapornpong
PRPawinee Rerknimitr
Pawinee Rerknimitr
NNNontaya Nakkam
Nontaya Nakkam
NSNiwat Saksit
Niwat Saksit
CSCHONLAPHAT Sukasem
CHONLAPHAT Sukasem
Objectives A previous publication in Chinese leprosy patients showed that the HLA-B*13:01 allele is a strong genetic marker for dapsone-induced drug hypersensitivity reactions, however there are no data describing whether HLA-B*13:01 is a valid marker for prediction of dapsone-induced drug hypersensitivity reactions in other ethnicities or nonleprosy patients. The aim of this study is to investigate whether there is an association between HLA genotypes and dapsone-induced severe cutaneous adverse reactions (SCARs) in Thai nonleprosy patients. Patients and methods HLA-B genotypes of 15 patients with dapsone-induced SCARs (11 drug reaction with eosinophilia and systemic symptoms, 4 Stevens–Johnson syndrome/toxic epidermal necrolysis), 29 control patients, and 986 subjects from the general Thai population were determined by the reverse PCR sequence-specific oligonucleotides probe. Results The HLA-B*13:01 allele was significantly associated with dapsone-induced SCARs compared with dapsone-tolerant controls (odds ratio: 54.00, 95% confidence interval: 7.96–366.16, P=0.0001) and the general population (odds ratio: 26.11, 95% confidence interval: 7.27–93.75, P=0.0001). In addition, HLA-B*13:01 associated with dapsone-induced SJS-TEN (OR: 40.50, 95% confidence interval: 2.78-591.01, P=0.0070) and DRESS (OR: 60.75, 95% confidence interval: 7.44-496.18, P=0.0001). Conclusion This study demonstrated an association between HLA-B*13:01 and dapsone-induced SCARs including Stevens–Johnson syndrome/toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms in nonleprosy patients. Moreover, these results suggest that the HLA-B*13:01 allele may be a useful genetic marker for prediction of dapsone-induced SCARs in Thai and Han-Chinese populations.

30 September 2018 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
SSShih‐Chi Su
Shih‐Chi Su
CCChun‐Bing Chen
Chun‐Bing Chen
WCWan‐Chun Chang
Wan‐Chun Chang
CWChuang‐Wei Wang
Chuang‐Wei Wang
WFWen‐Lang Fan
Wen‐Lang Fan
WCWenHung Chung
WenHung Chung

1 July 2017 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
PDF file
NSNiwat Saksit
Niwat Saksit
WTWichittra Tassaneeyakul
Wichittra Tassaneeyakul
NNNontaya Nakkam
Nontaya Nakkam
PKParinya Konyoung
Parinya Konyoung
UKUsanee Khunarkornsiri
Usanee Khunarkornsiri
WTWongwiwat Tassaneeyakul
Wongwiwat Tassaneeyakul
Allopurinol is one of the most common causes of severe cutaneous adverse drug reactions (SCARs) including drug reactions with eosinophilia and systemic symptoms (DRESS), Stevens–Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). This study identified the risk factors associated with the development of allopurinol-induced SCARs in a Thai population. Eighty-six allopurinol-induced SCARs (i.e. 19 DRESS and 67 SJS/TEN) and 182 allopurinol-tolerant patients were enrolled in the study. The HLA-B*58:01 allele was determined. Clinical and medicinal data were collected. Results from multivariate analysis showed that only the HLA-B*58:01 and female sex were identified as risk factors of allopurinol-induced SCARs in this Thai population. Patients who carried the HLA-B*58:01 allele were at a higher risk of allopurinol-induced DRESS [odds ratio (OR)=149.2, 95% confidence interval (CI)=24.0–∞, P<1.00×10−4]. Similar results were observed in allopurinol-induced SJS/TEN (OR=175.0, 95% CI=44.3–690.9, P=1.69×10−13). The risk of allopurinol-induced SCARs in women was higher than that in men (OR=4.6, 95% CI=1.4–15.6, P=1.44×10−2). The overall mortality rate of allopurinol-induced SCARs was 11.39% and a higher mortality rate was observed in elderly women. Among the risk factors identified, the HLA-B*58:01 allele had the greatest impact on the development of both phenotypes of allopurinol-induced SCARs in this studied Thai population. In case HLA-B*58:01 genotyping cannot be accessed, close monitoring of allopurinol usage, especially in elderly women with impaired renal function, is necessary to reduce the mortality rate of these life-threatening SCARs.

6 August 2018 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
NNNontaya Nakkam
Nontaya Nakkam
PKParinya Konyoung
Parinya Konyoung
SKSirimas Kanjanawart
Sirimas Kanjanawart
NSNiwat Saksit
Niwat Saksit
TKThachanan Kongpan
Thachanan Kongpan
WTWichittra Tassaneeyakul
Wichittra Tassaneeyakul
Severe cutaneous adverse drug reactions (SCARs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reactions with eosinophilia and systemic symptoms (DRESS) are potentially life-threatening cutaneous reactions caused by several drugs. Recently, a number of genes encoding for human antigen presenting proteins, HLA alleles, have been discovered as valid pharmacogenetic markers for prediction of these life-threatening reactions. This study was aimed to determine the distribution of HLA alleles including the HLA class I and class II genes in 183 unrelated individuals of a Thai population using high resolution HLA genotyping in order to obtain 2-field data (4-digit resolution) and compare the frequencies of the HLA alleles that have been proposed as markers of SCARs with other ethnics. Results revealed a high prevalence of pharmacogenetic markers of drug-induced SCARs e.g., B*13:01 for dapsone; B*15:02 for carbamazepine and oxcarbazepine; B*58:01, A*33:03 and C*03:02 for allopurinol; C*08:01, C*14:02 and DRB1*12:02 for co-trimoxazole. Whereas, low prevalence of pharmacogenetic markers of SCARs induced by abacavir, B*57:01 and phenytoin, B*56:02/B*56:04 were noticed. The allele frequencies of B*13:01, B*15:02, and B*58:01 observed in a Thai population were significantly higher than those reported in Japanese and Caucasian populations. Similar to those observed in other Southeast Asian populations, low frequencies of A*31:01 and B*57:01 alleles were noted in the study population. Based on the frequencies of HLA pharmacogenetic markers, Thai and other Southeast Asian populations may at higher risk of drug-induced SCARs compared with Caucasian population.

17 December 2017 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
NSNiwat Saksit
Niwat Saksit
NNNontaya Nakkam
Nontaya Nakkam
PKParinya Konyoung
Parinya Konyoung
UKUsanee Khunarkornsiri
Usanee Khunarkornsiri
PCPansu Chumworathayi
Pansu Chumworathayi
WTWichittra Tassaneeyakul
Wichittra Tassaneeyakul
Severe cutaneous adverse drug reactions (SCARs) are life-threatening reactions. The strong association between theHLA-B∗58 : 01allele and allopurinol-induced SCARs is well recognized. Screening forHLA-B∗58 : 01allele before prescribing allopurinol in some populations has been recommended. Several single-nucleotide polymorphisms (SNPs) in chromosome 6 have been found to be tightly linked with theHLAallele, and these SNPs have been proposed as surrogate markers of theHLA-B∗58 : 01allele. This study aimed to evaluate the association between three SNPs in chromosome 6 and allopurinol-induced SCARs in a Thai population. The linkage disequilibrium between theHLA-B∗58 : 01allele and these SNPs was also evaluated. Results showed that three SNPs including rs9263726, rs2734583, and rs3099844 were significantly associated with allopurinol-induced SCARs but with a lower degree of association when compared with theHLA-B∗58 : 01allele. The sensitivity, specificity, PPV, and NPV of these SNPs were comparable to those of theHLA-B∗58 : 01allele. Although detection of the SNP is simpler and less expensive compared with that of theHLA-B∗58 : 01allele, these SNPs were not perfectly linked with theHLA-B∗58 : 01allele. Screening using these SNPs as surrogate markers of theHLA-B∗58 : 01allele to avoid SCARs prior to allopurinol administration needs caution because of their imperfect linkage with theHLA-B∗58 : 01allele.